دورية أكاديمية
Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?
| العنوان: | Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage? |
|---|---|
| المؤلفون: | Marticorena, J, Romano, MR, Gibran, SK, Heimann, H, Wong, D |
| بيانات النشر: | //www.eur-j-ophthalmol.com/ejo Italy |
| سنة النشر: | 2009 |
| المجموعة: | University of Hong Kong: HKU Scholars Hub |
| مصطلحات موضوعية: | Intraoperative bevacizumab injection, Proliferative diabetic retinopathy, Vitreous hemorrhage, Adult, Vitreous Hemorrhage - Etiology - Prevention & Control, Vitreous Body, Vitrectomy, Visual Acuity, Vascular Endothelial Growth Factor A - Antagonists & Inhibitors, Recurrence - Prevention & Control, Prospective Studies, Postoperative Complications, Pilot Projects, Middle Aged, Male, Intraoperative Care, Injections, Humans, Female, Diabetic Retinopathy - Etiology - Prevention & Control, Cataract - Etiology, Antibodies, Monoclonal, Humanized, Monoclonal - Administration & Dosage, Angiogenesis Inhibitors - Administration & Dosage, Aged |
| الوصف: | Purpose. To evaluate the recurrence of vitreous hemorrhage (VH) in patients treated with intravitreal bevacizumab (IVB) injection (2.5 mg/ 0.1 mL) intraoperatively at the end of vitrectomy for treatment of diabetic nonclearing VH. Methods. A prospective pilot study of 30 eyes of 28 consecutive diabetic patients who underwent pars plana vitrectomy and IVB injection intraoperatively at the end of vitrectomy was performed. The amount of VH was graded with slit lamp biomicroscopy by three masked retinal specialists from grade 0 to grade 3. Main outcome measures were rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results. The percentage of severe recurrent VH with no fundus details (grade 3) was 7%, 13%, 27%, and 30%, respectively, at 7 days and 1-, 3-, and 6-month follow-up. At 6-month follow-up, the best-corrected visual acuity improved from 1.00 to 0.4 logMAR (p=0.01) in 21 out of 30 eyes (70%). Nine out 20 (40%) phakic patients developed cataract during the follow-up period, and 7 (31%) of them underwent cataract surgery. Conclusions. The study suggests that intravitreal bevacizumab injection cannot prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous hemorrhage. © Wichtig Editore, 2009. ; link_to_subscribed_fulltext |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| ردمك: | 978-0-00-271844-8 0-00-271844-8 |
| تدمد: | 1120-6721 |
| العلاقة: | European Journal of Ophthalmology; http://www.scopus.com/mlt/select.url?eid=2-s2.0-70349473580&selection=ref&src=s&origin=recordpageTest; European Journal Of Ophthalmology, 2009, v. 19 n. 4, p. 618-621; 621; 165356; WOS:000271844800016; eid_2-s2.0-70349473580; 618; http://hdl.handle.net/10722/146307Test; 19 |
| الإتاحة: | http://hdl.handle.net/10722/146307Test |
| رقم الانضمام: | edsbas.977CC28 |
| قاعدة البيانات: | BASE |
Full Text Finder | ردمك: | 9780002718448 0002718448 |
|---|---|
| تدمد: | 11206721 |